12
Participants
Start Date
February 29, 2004
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Rituximab
250 mg/m\^2 IV over 4-6 hours for 2 weeks.
Zevalin
5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Biogen
INDUSTRY
M.D. Anderson Cancer Center
OTHER